Weekly docetaxel for patients with platinum/paclitaxel/irinotecan-resistant relapsed ovarian cancer: a phase I study

被引：9
|
作者：
Fumitoshi Terauchi
Takayuki Hirano
Hideki Taoka
Kazuo Masaki
Yasuhiro Yamamoto
Hisao Ogura
Harumi Kubo
机构：
[1] Toho University School of Medicine,Second Department of Obstetrics and Gynecology
[2] Tokyo Metropolitan Ebara Hospital,Obstetrics and Gynecology
[3] Toho University School of Medicine,First Department of Obstetrics and Gynecology
来源：
International Journal of Clinical Oncology | 2003年 / 8卷 / 6期
关键词：
Relapsed ovarian cancer; Weekly docetaxel; Phase I study;
D O I：
10.1007/s10147-003-0351-7
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：348 / 351
页数：3
相关论文
共 50 条
  • [1] A phase II study of irinotecan and docetaxel in patients with platinum-resistant relapsed epithelial ovarian cancer
    Matsumoto, T.
    Hiura, M.
    Oshita, T.
    Hirata, E.
    Shiroyama, Y.
    Wroblewski, J.
    Yokoyama, T.
    Nogawa, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients
    Kaern, J
    Baekelandt, M
    Tropé, CH
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2002, 23 (05) : 383 - 389
  • [3] Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer
    Fennelly, D
    Aghajanian, C
    Shapiro, F
    OFlaherty, C
    McKenzie, M
    OConnor, C
    Tong, W
    Norton, L
    Spriggs, D
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) : 187 - 192
  • [4] Early termination of a phase II study of the Austrian AGO: Weekly docetaxel and irinotecan in platinum-refractory and resistant ovarian cancer
    Petru, E.
    Angleitner-Boubenizek, L.
    Reinthaller, A.
    Volgger, B.
    Kohlberger, P.
    Deibi, M.
    Bogner, G.
    Wolfram, G.
    Marth, C.
    EJC SUPPLEMENTS, 2007, 5 (04): : 319 - 319
  • [5] Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer
    Garcia, AA
    O'Meara, A
    Bahador, A
    Facio, G
    Jeffers, S
    Kim, DY
    Roman, L
    GYNECOLOGIC ONCOLOGY, 2004, 93 (02) : 493 - 498
  • [6] A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer
    Leiser, A. L.
    Maluf, F. C.
    Chi, D. S.
    Sabbatini, P.
    Hensley, M. L.
    Schwartz, L.
    Venkatraman, E.
    Spriggs, D.
    Aghajanian, C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2007, 17 (02) : 379 - 386
  • [7] Weekly gemcitabine in patients with relapsed platinum-resistant ovarian or peritoneal cancer. Results of phase II study
    Czerniawska, Malgorzata
    Jagiello-Gruszfeld, Agnieszka
    Zbrzezniak, Jolanta
    Wachula, Ewa
    Szablowska-Siwik, Sylwia
    Sikorska, Magdalena
    ANNALS OF ONCOLOGY, 2006, 17 : 172 - 172
  • [8] Paclitaxel injectable emulsion: Phase 2a study of weekly administration in patients with platinum-resistant ovarian cancer
    Lissianskaya, A
    Gershanovich, M
    Ognerubov, N
    Golubeva, O
    Pratt, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 460S - 460S
  • [9] PHASE 2 TRIAL OF WEEKLY PACLITAXEL WITH PEMBROLIZUMAB IN PLATINUM RESISTANT RECURRENT OVARIAN CANCER
    Wenham, R. M.
    McGuire, W.
    Fridley, B.
    Boulware, D.
    Apte, S.
    Chon, H.
    Shahzad, M.
    Secord, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 20 - 20
  • [10] WEEKLY PACLITAXEL-CARBOPLATINUM IS EFFECTIVE IN PLATINUM-RESISTANT OVARIAN CANCER PATIENTS AFTER PREVIOUS WEEKLY PACLITAXEL
    Concin, N.
    Salihi, R.
    Lage, T.
    Van Nieuwenhuysen, E.
    Neven, P.
    Vergote, I.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 664 - 664
12345